Sandostatin LAR

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:activities inhibits growth hormone release
gptkbp:availability prescription only
gptkbp:category minimal
Category B
gptkbp:class endocrine therapy
somatostatin analogue
gptkbp:clinical_trial Phase III
long-term management
gptkbp:community_service not established
gptkbp:contraindication hypersensitivity to octreotide
gptkbp:dosage_form sustained-release injection
gptkbp:education instruct on injection technique
gptkbp:effective_date gptkb:2003
FDA approved
gptkbp:formulation powder for suspension
gptkbp:frequency once every 4 weeks
https://www.w3.org/2000/01/rdf-schema#label Sandostatin LAR
gptkbp:indication treatment of neuroendocrine tumors
gptkbp:ingredients gptkb:octreotide
gptkbp:interacts_with may interact with insulin
gptkbp:is_atype_of H01 C B02
gptkbp:is_monitored_by monitor glucose levels
gptkbp:is_used_for acromegaly
VI Poma
carcinoid syndrome
gptkbp:lifespan 2 hours
gptkbp:manager intramuscular injection
gptkbp:manufacturer gptkb:Novartis
gptkbp:marketed_as Sandostatin LAR Depot
gptkbp:packaging vial
gptkbp:pharmacokinetics bioavailability varies with route
gptkbp:price varies by region
gptkbp:products lanreotide
pasireotide
gptkbp:provides_information_on included in treatment protocols for acromegaly
gptkbp:requires gptkb:theorem
gptkbp:research ongoing for efficacy in other conditions
gptkbp:rounds hepatic metabolism
gptkbp:safety_features monitor for gallbladder disease
gptkbp:scholarships available through manufacturer programs
gptkbp:shelf_life 24 months
gptkbp:side_effect fatigue
headache
nausea
abdominal pain
diarrhea
gastrointestinal disturbances
gptkbp:social_structure C49 H66 N10 O10 S
gptkbp:storage store at 2-8° C
gptkbp:technique deep intramuscular injection
gptkbp:bfsParent gptkb:octreotide
gptkbp:bfsLayer 7